Dishman Carbogen Amcis Ltd
About
Dishman Carbogen Amcis Limited is a global pharmaceutical company specializing in active pharmaceutical ingredients (APIs) and contract development and manufacturing services (CDMO). With operations spanning multiple countries, the company provides high-quality, cost-effective solutions to pharmaceutical and biotechnology firms worldwide. It focuses on innovation, offering a comprehensive range of services from early-stage drug development to commercial-scale production. Dishman’s expertise in complex chemistry, regulatory compliance, and custom synthesis enables it to cater to diverse therapeutic segments. By integrating cutting-edge technology and a strong R&D foundation, the company plays a crucial role in the global pharmaceutical supply chain.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 2648 3.7% | 2554 16.3% | 2197 14.6% | 1917 -9.0% | 2106 0.9% | 2087 15.6% | 1806 3.8% | 1740 - | 7 1484.4% | 0 - |
| Net Operating Income (INR Cr) | 2616 8.41% | 2413 12.72% | 2141 11.96% | 1912 -6.44% | 2044 -0.73% | 2059 21.47% | 1695 -1.10% | 1714 0.00% | 7 0.00% | 0 0.00% |
| Profit (INR Cr) | -153 - | -30 - | 18 - | -165 - | 159 -24.6% | 210 36.1% | 155 6.3% | 145 - | 1 - | -1 - |
| Assets (INR Cr) | 8768 4.2% | 8419 7.8% | 7809 2.7% | 7604 3.2% | 7367 10.5% | 6670 3.6% | 6437 7.5% | 5990 - | 9 -3.8% | 10 - |
| Net Worth (INR Cr) | 5628 -3.1% | 5810 4.7% | 5549 -2.6% | 5699 -0.3% | 5715 6.3% | 5379 5.3% | 5107 6.1% | 4814 0.0% | 0 -160.7% | -1 0.0% |
| Employee Cost (INR Cr) | 1208 17.3% | 1030 4.9% | 981 12.4% | 873 14.5% | 762 6.7% | 715 14.3% | 625 4.9% | 596 - | 0 - | 0 - |
| Interest Cost (INR Cr) | 120 | 86 | 57 | 48 | 62 | 57 | 49 | 49 | 1 | 1 |
| Cash & Bank Balance (INR Cr) | 413 | 189 | 172 | 308 | 161 | 96 | 69 | 87 | 1 | 0 |
| Total Debt (INR Cr) | 2313 | 2209 | 1830 | 1589 | 1357 | 1042 | 1095 | 950 | 9 | 10 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | - | - | 0.8% | - | 7.5% | 10.1% | 8.6% | 8.4% | 12.5% | - |
| Profit As % Of Assets | - | - | 0.2% | - | 2.2% | 3.2% | 2.4% | 2.4% | 9.6% | - |
| Profit As % Of Networth | - | - | 0.3% | - | 2.8% | 3.9% | 3.0% | 3.0% | 261.8% | - |
| Interest Cost to EBITDA % | 42.8% | 30.2% | 17.9% | 18.9% | 12.5% | 10.3% | 11.0% | 10.8% | 58.9% | - |
| Debt to Equity Ratio | 0.41 | 0.38 | 0.33 | 0.28 | 0.24 | 0.19 | 0.21 | 0.20 | 26.41 | - |
| RONW | - | - | 0.9% | - | 2.9% | 4.0% | 3.1% | 3.0% | 261.8% | - |
| ROCE | 0.0% | 1.0% | 0.8% | 0.0% | 3.7% | 5.6% | 4.5% | 4.4% | 21.5% | 0.0% |